Genentech’s Tecentriq Receives FDA Approval a Combination Therapy, for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations

 Genentech’s Tecentriq Receives FDA Approval a Combination Therapy, for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations

Genentech’s Tecentriq Receives FDA Approval a Combination Therapy, for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations

Shots:

  • The approval is based on P-III IMpower150 study results assessing Tecentriq + CT (paclitaxel & carboplatin) + Avastin (bevacizumab) (w or w/o) in 1202 patients in ratio (1:1:1) with Stage IV or recurrent mNon-sq NSCLC not treated with CT
  • P-III IMpower150 study results (Tecentriq + carboplatin and paclitaxel, Tecentriq +Avastin + carboplatin & paclitaxel, Avastin + carboplatin & paclitaxel): OS (19.2 vs 14.7 mos.); reduced risk of disease worsening or death 29%, ORR (55% vs 42%); CR 4%; PR 51%; mDOR (10.8 vs 6.5 mos.)
  • Tecentriq is a mAb used for binding PD-L1 protein, while blocking interaction with PD-1 and B7.1 receptors

 

Click here to read full press release/ article | Ref: Genentech| Image: Nature

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post